Skip to Main Content

Hello, everyone, and nice to see you again after an extended weekend break on this side of the pond. We hope the respite was invigorating and relaxing, because that oh-so-familiar routine of meetings, deadlines, calls, and the like has, of course, returned. But what can you do? The world keeps spinning, no matter how much we may try to slow its pace. So time to forge ahead. Grab a cup of stimulation and peruse some tidbits as you start the journey. Hope all goes well and, as always, please do keep in touch. …

Mallinckrodt (MNK) plans to spin off its generics unit and keep the Amitiza constipation medicine as part of its branded-drugs business, which will be renamed Sonorant Therapeutics, Reuters tells us. Last December, the company indicated it was open to a sale of the generics business or would spin it off in the second half of 2019, and that Amitiza would be part of the spun-off unit. The drug maker believes the new generics company, to be called Mallinckrodt, will emerge with less debt than previously anticipated without the Amitiza drug.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!